Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference

Saturday, March 1, 2008 General News J E 4
HAYWARD, Calif., Feb. 29 Kosan BiosciencesIncorporated (Nasdaq: KOSN) announced today that Gary S. Titus, Kosan's SeniorVice President and Chief Financial Officer, will present at the SusquehannaSecond Annual SIGnificant Options in Healthcare Conference in New York at theW Hotel on Tuesday, March 4, 2008 at 10:30 a.m. EST. A live webcast of thepresentation can be accessed through

Interested parties may also access a live webcast of the presentation byvisiting the "Events Calendar" page under the "Investors/Press" tab on Kosan'swebsite at A recorded replay of the presentations willbe available for two weeks.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes ofanticancer agents through clinical development -- Hsp90 (heat shock protein90) inhibitors and epothilones. Hsp90 inhibitors have a novel mechanism ofaction targeting multiple pathways involved in cancer cell growth andsurvival. Tanespimycin (KOS-953) is being tested in combination withbortezomib (Velcade(R)) in patients with multiple myeloma in a clinicalprogram called TIME. Tanespimycin is also being studied in HER2-positivemetastatic breast cancer in combination with trastuzumab (Herceptin(R)).Epothilones inhibit cell division with a mechanism of action similar totaxanes, one of the most successful classes of anti-tumor agents. KOS-1584 isin Phase 1 clinical trials in patients with solid tumors. Kosan's motilinagonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial ingastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit thecompany's website at

Velcade(R) (bortezomib) is a registered trademark of MillenniumPharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.

SOURCE Kosan Biosciences Incorporated


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for t...
Qiao Xing Mobile's CECT Subsidiary Releases Newest...